



Year-end report January - December 2008

STRONG POSITION ON A WEAK MARKET

- Net turnover for the quarter amounted to MSEK 23.6 (27.4) and for the year to MSEK 83.1 (101.9).
- Operating loss for the quarter excluding one-off write-down and restructuring costs amounted to MSEK -12.9 (-8.2) and including the one-off items to MSEK -24.6 (-26.9).
Operating loss for the year excluding one-off write-down and restructuring costs was MSEK -31.3 (-25.6), and, adjusted for exchange rate effects in North America, MSEK -26.6 (-28.4).
Operating loss including the one-off items amounted to MSEK -41.9 (-50.7).
- Cash flow during the quarter was MSEK -3.2 (-5.8) and the equity ratio for the year was 59% (64%).
- Loss per share for the quarter was SEK -1.11 (-1.74) and for the year to SEK -2.11 (-2.90).
- The first order for MobiMed on commercial terms in Germany was received during the fourth quarter and continued strong growth was shown in the North American operation.

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

- Renegotiation and extension of the company's previously raised syndicate loans have taken place.

www.ortivus.se



Ortivus offers unique solutions by combining expertise in wireless, IT and medical technology with clinical knowledge. Ortivus solutions secure that the patient get accurate medical treatment and expertise instantly throughout the care process. This results in better medical outcome as well as improved efficiency for the entire health care system.

FACTS ABOUT ORTIVUS

Ortivus is a listed company on NASDAQ OMX Stockholm Small Cap-list and was founded in 1985. It is based in Danderyd, Sweden. Ortivus has 100 employees in Sweden, US, Canada and Great Britain. In total more than 2 600 emergency services, 1 000 ambulances and 500 hospital beds are equipped with Ortivus solutions.

MD's REPORT

Continued strong sales growth in USA despite austere economy

Considerable measures have been introduced to turn around Ortivus' negative profit growth.

Business has been affected by slower decision-making processes in the austere economic situation, but we have found continued great interest in Ortivus' solutions. We are seeing continued strivings to ensure safer and more effective care of heart attack patients in particular during the acute stage. In general, we are noting increased interest from many countries in improving the nursing outcome, patient safety and cost effectiveness, which are facilitated by Ortivus' products and solutions.

The underlying North American operation generates continued positive profit and cash flow, despite the austere economy. We are pleased to report that net turnover in USA has increased by just over 7% compared to last year.

One step in the work of turning around the financial development of Ortivus was the introduction of a programme to reduce costs during the fourth quarter.

A strategy focusing on Ortivus' areas of strength was started in 2008, with the sale of the German company Medos, which provides solutions for radiology information systems. An initiative to develop and introduce new business models has started. The first step is to introduce software assurance, where the customer enters into a contract for continuous updates of the software. Reactions from the market have been positive.

The internal efficiency work is continuing, now with intensive focus on completing a number of business deals on a couple of priority markets.

We are seeing continued great interest on the Nordic market, and in particular the Swedish market, to increase efficiency and improve healthcare through ensuring Prehospital eHealth. This entails, among other things, high quality care already during ambulance transport. This assumes immediate and continuous contact between ambulances and clinical experts, which Ortivus' solutions facilitate. This provides a basis for decisions to transport patients to the relevant care or therapy location. It also leads to better care outcomes,

safer care for the patient and in total also to lower care costs.

The striving of healthcare towards increased regionalization and centralization of specialist competence is increasingly demanding that patients get access to specialist competence already during transport.

Two thirds of Swedish ambulances are today equipped with Ortivus' solution MobiMed. CoroNet, with its unique telemetry solution for heart patients, is represented at the majority of leading university hospitals in Sweden.

We are seeing increased activities in many countries to introduce national IT solutions to support healthcare, among them the UK and Sweden. Coordinated records handling is another area where Ortivus is far ahead in development and is well positioned with its products. During the period, a Letter of Intent has been entered into with Excense, a software handling company, which supports Ortivus' solution for records handling and decision support for heart patients in accordance with the national guidelines.

As previously communicated, on the British IT market, the considerable national initiative for coordinated IT handling within healthcare has been delayed. Ortivus is continuing its marketing efforts and our activities in the UK have increased. On the German market, Ortivus has received its first commercial MobiMed order, which is an important break into a large market. The North American operation generates continued positive profit and cash flow, despite the austere economy. During the year, we have completed a large development project, outside the company's core area, which has led to considerable write-down. We have completed an MD change, and now have an internally recruited MD with many years of experience of Emergency Medical Services and our customers. We are now focusing on further developing our services within this area.

In these unsettled times, it is a strength to have such a stable circle of owners, which has also been confirmed by the renegotiated syndicate loan.

We are seeing continued strong interest in Ortivus' offering, but procurement processes are lengthy. Despite the demanding market situation, I look on the future with confidence. Ortivus has a well-positioned and unique offering to customers throughout the world, with great growth potential, and now our aim is to achieve a positive cash flow during the fourth quarter of 2009.

Jan B Andersson
MD

23 February 2009

Year-end report

January - December 2008

FOURTH QUARTER 2008

Net turnover for the group during the fourth quarter amounted to MSEK 23.6 (27.4), which was a reduction of just over 13%. The reduction was mainly due to lower turnover in Sweden, unchanged turnover on the US market, while UK sales increased by MSEK 1.4.

Operating profit for the fourth quarter amounted to MSEK -24.6 (-26.9).

Operating costs for the fourth quarter amounted to MSEK -40.5 (-46.6) including write-down of intangible assets in North America during 2008 of MSEK -9.5 and in Sweden during 2007 of MSEK -18.7. Reservation in conjunction with MD change in US amounted to MSEK -2.2.

Profit before tax for the quarter amounted to MSEK -24.3 (-27.5).

Cash flow for the fourth quarter amounted to MSEK -3.2 (-5.8).

Despite the unsettled US economy, Ortivus' US operation showed an underlying positive result and cash flow. A new MD for the American company has been appointed, Teresa Ruroden, with many years' experience of Ortivus and the industry.

As communicated in the Q3 report, in order to further strengthen Ortivus' access to financing, the existing bank credit has been renegotiated and strengthened by a further credit facility. In addition, an agreement to pay interest only on the bank loans for 12 months has been reached with the bank.

FULL YEAR 2008

RESULT AND POSITION

Sales

Net sales for the group for the full year amounted to MSEK 83.1 (101.9).

The reduction in the Nordic countries was due mainly to lower sales on the Swedish market, but also a reduction of MSEK 3.3 through the closure of the Danish subsidiary. In Europe, the reduction is due to the UK.

In the US, turnover in local currency increased by 7%. For North America, turnover fell by 10% due to reduced sales to the segment police/fire service, and a negative exchange rate component equivalent to MSEK 1.5.

Gross profit, expenses and operating profit

Gross profit for the group for the full year amounted to MSEK 60.6 (76.1). The gross margin is in the main unchanged from 75% to 73%.

Operating costs for the group for the full year amounted to MSEK -102.4 (-126.9). The reduction in operating costs of just over 19% is primarily a result of the considerable programme of measures that has been completed.

Operating loss for the group for the full year amounted to MSEK -41.9 (-50.7). Depreciation and write-down of intangible fixed assets amounted to MSEK -17.1 (-30.5). Operating loss for the year excluding write-down and structural reserves according to the table below amounted to MSEK -31.3 (-25.6), and adjusted for exchange rate effects in North America to MSEK -26.6 (-28.4). Exchange rate effects in the North American companies amounted to MSEK -4.7 (2.8).

The operating profit for North America, adjusted for one-off write-down and structural reserves continues positive, with positive cash flow, but it affected by exchange rate effects and loss of sales in individual segments. In the North American operation, the dominant segment ambulance continues to develop positively, and order reception during the quarter has been strong. The efforts made in the smaller segment are delayed. The investment in developing the new system platform continues, which creates a good basis for continued marketing and sales of the North American products.

Capitalized expenses during the full year amounted to MSEK 8.2 (18.3), of which capitalized development expenses for CoroNet and MobiMed amounted to MSEK 4.4 (12.5).

Result, net financial items and tax for the period

Loss after tax for the quarter for the remaining operation amounted to MSEK -22.9 (-36.1), which corresponds to a loss per share before and after dilution of SEK -1.11 (-1.74). Loss after tax for the year for the remaining operation amounted to MSEK -43.7 (-60.1), which corresponds to a loss per share before and after dilution of SEK -2.11 (-2.90).

Current tax relates to North America. No deductible deficiency has been capitalized in the group or the companies.

As a step in Ortivus' programme of measures focusing on core areas, the German subsidiary Medos AG, operating within image handling for X-ray, has been sold. Loss after tax from the operation sold amounted to MSEK -25.2 and relates to Medos AG. Of the MSEK -25.2, MSEK -27.2 consists of write-down accounted for during the second quarter of 2008. During the third quarter, the purchase price of MEUR 2.2 was paid and the transaction thus completed.

In order to strengthen liquidity, a loan of MSEK 25 was raised during the second quarter from some of the company's larger shareholders.

Option programme

As previously communicated, Ortivus' board has decided on a share-price related bonus programme for all employees in the parent company who are not included in the subscription option programme for top executives. The subscription option programme for top executives covers 500,000 subscription options and is fully subscribed. The aim of the programmes is to create increased focus on shareholder value in the ongoing work of change within Ortivus, and to create further motivation and commitment among employees.

Change of MD

Jan B Andersson, with experience from both medical-technical companies and IT companies, was recruited as the new MD for the company. Jan B Andersson most recently worked for TietoEnator, where he was the head of all health and medical care operations in Scandinavia. Jan B Andersson took up his position on 11 August 2008.

Segment, continued operations ⁽¹⁾

<i>MSEK Jan-Dec</i>	<i>North America</i>		<i>Europe excl. Nordic</i>		<i>Nordic & Other</i>		<i>Eliminations</i>		<i>Group</i>	
	<i>2008</i>	<i>2007</i>	<i>2008</i>	<i>2007</i>	<i>2008</i>	<i>2007</i>	<i>2008</i>	<i>2007</i>	<i>2008</i>	<i>2007</i>
External sales	56,3	62,9	8,2	10,4	18,7	28,7	0,0	0,0	83,1	101,9
Internal sales	0,0	0,0	0,0	0,0	5,7	1,1	-5,7	-1,1	0,0	0,0
Net Sales	56,3	62,9	8,2	10,4	24,4	29,8	-5,7	-1,1	83,1	101,9
Operating profit/loss	-10,3	10,6	-2,9	0,3	-28,7	-58,3	-0,1	-3,3	-41,9	-50,7
Operating profit excl write-downs and structural reserves	1,4	10,6	-2,9	0,3	-29,8	-33,2	-0,1	-3,3	-31,3	-25,6

Sales, continued operations

<i>MSEK Net Sales</i>	<i>2008</i>	<i>2007</i>	<i>Change</i>	<i>2008</i>	<i>2007</i>	<i>Change</i>
	<i>Oct - Dec</i>	<i>Okt - Dec</i>	<i>%</i>	<i>Jan - Dec</i>	<i>Jan - Dec</i>	<i>%</i>
North America	15,6	16,7	-6,6	56,3	62,9	-10,5
Europe (excl Nordic)	2,4	1,0	140,0	8,2	10,4	-21,2
Nordic (& other regions)	5,6	9,7	-42,3	18,7	28,7	-34,8
Total	23,6	27,4	-13,9	83,1	101,9	-18,4

¹⁾ Continued operations exclude the former subsidiary Medos AG, which was sold during the year.

Cash flow, investments and liquidity

Current operations produced a cash flow for the full year of MSEK -11.1 (-32.9) and was affected by restructuring expenses in Germany amounting to MSEK -6.0 (-5.1). In the US, a reservation for the change of MD has an effect of MSEK -2.2 (-).

Investments for the fourth quarter amounted to MSEK 4.2 (-2.2).

Investments for the year amounted to MSEK -0.4 (-23.0) and consisted of acquisition of intangible fixed assets of MSEK -8.2 (-18.3), tangible fixed assets of MSEK -4.5 (-5.3), disposal of financial assets of MSEK 6.3 (0.5), and of disposal of Medos AG for MSEK 6.0.

Financing operations for the fourth quarter amounted to MSEK -1.1 (-2.2).

Financing operations produced a cash flow for the full year of MSEK 8.2 (-8.5). During 2008, the company raised a loan from some of the larger shareholders of MSEK 25, made an extra loan repayment of MSEK -8, received the purchase price of MEUR 2.2 from the sale of Medos and made a further loan repayment of MSEK -4.4 on a loan related to the acquisition of Medos.

Cash flow for the year was MSEK -11.1 (-32.9). At the end of the year, liquid assets for the group amounted to MSEK 50.5 (57.2). Current investments amounted to MSEK 1.4 (8.2).

Net financial items for the group amounted to MSEK -2.0 (-0.4) and the group's debt ratio was 0.27x (0.13x).

Parent company

Net turnover for the parent company was MSEK 24.4 (26.4) and the loss after financial items was MSEK -55.5 (-59.1). Loss after financial items adjusted for the loss at the sale of Medos amounted to MSEK -38.7. At the end of the year, cash and bank balances for the group amounted to MSEK 20.7 (22.2). During the year, the company invested in intangible assets relating to balanced development expenses in an amount of MSEK 4.4 (12.5).

Staff

The average number of employees in the group was 98 (157) persons.

Significant risks and uncertainty factors

The identified risks and uncertainty factors that in particular may affect Ortivus' sales, result and cash flow are primarily:

Export efforts on priority markets

During 2007, the strategy for expansion outside established markets was changed. The selected markets are worked together with partners, where such are present, and on the remaining markets partners are sought. Sales and procurement times are relatively long, difficult to assess and complex, which together continue to make the short to medium business situation difficult to assess.

Economic crisis and world business cycle

The crisis in the financial markets and the general recession around the world may affect Ortivus as well as its customers, both in operational and financial terms. The effect on Ortivus' business operation is as yet regarded as relatively limited, but is difficult to survey at the moment.

In addition to the above and the risks described in the management report for 2007, no further significant risks are deemed to have been added.

All forward-looking statements in this report are based on the company's best assessment at the time of the report. Like all assessments of the future, such statements include risks and uncertainties that may lead to the actual outcome being different.

Events after the end of the reporting period

Renegotiation and extension of the company's previously raised syndicate loans have taken place.

Accounting policies

This year-end report has been drawn up for the group in accordance with IAS 34 Interim reporting. The parent company has drawn up its financial reporting in accordance with the Annual Accounts Act and RFR 2.1 Accounting for legal entities. The group and parent company accounting policies and calculation methods are unchanged compared to the annual accounts for 2007.

Dividends

The board proposes that no dividend is paid for the financial year 2008.

Annual general meeting

The annual general meeting will be held on 6 May 2009 at 3pm, in the conference centre Spårvagnshallarna, Birger Jarlsgatan 57A, in Stockholm. Notice and proposals for the AGM will be available on the company's website www.ortivus.com.

Prospects for the group 2009

During 2009, the work of safeguarding long-term profitability will continue, including a review of the group structure. Market development for 2009 is difficult to assess, but the company's strategic plan remains firm. This aims to achieve long-term stable profitability and positive cash flow during the latter part of 2009. Operations in North America are expected to continue to generate good profits. The efforts at increasing volumes outside the Nordic countries based on MobiMed and CoroNet are continuing, and are of decisive importance for the company's financial result. Several large business opportunities are being worked on, but when and how these can generate business is difficult to assess, even if the company has a positive view of the long-term profitability potential. However, the effort will entail a continued negative cash flow for the parent company during 2009. In total, the result for the group will be negative for 2009.

Table: Write-down and structural reserves

MSEK Jan-Dec	North America		Europe excl. Nordic		Nordic & Other		Eliminations		Group	
	2008	2007	2008	2007	2008	2007	2008	2007	2008	2007
Operating Expenses Total									-102,4	-126,9
Write-downs intangible assets	-9,5	-	-	-	-	-18,7	-	-	-9,5	-18,7
Severance pay to CEO in North America	-2,2	-	-	-	-	-	-	-	-2,2	-
Restructuring costs for the Swedish company	-	-	-	-	-	-1,5	-	-	-	-1,5
Severance pay to former CEO	-	-	-	-	1,1	-4,9	-	-	1,1	-4,9
<i>Total write-downs and reservations</i>	<i>-11,7</i>	<i>-</i>	<i>-</i>	<i>-</i>	<i>1,1</i>	<i>-25,1</i>	<i>-</i>	<i>-</i>	<i>-10,6</i>	<i>-25,1</i>
Operating expenses excl write-downs and structural reserves									-91,8	-101,8

Footnote: Operating costs for 2008 include a reversal of provision for severance pay for the former MD of MSEK 1.1, which was paid in full as per agreement. Operating costs for the previous year 2007 for remaining operations include reservation of MSEK -1.5 for restructuring the Swedish operation and MSEK -4.9 relating to severance pay to the former MD. In addition, exchange rate effects reduce the North American company's operating profit by MSEK -4.7 (2.8).

Danderyd, 23 February 2009

The Board
Ortivus AB (publ), Org.No 556259-1205,
Box 713, 182 17 Danderyd, Sweden

Future financial reports

The annual report for 2008 will be available on the company's website as from 21 April 2009

The interim report for the first quarter of 2009 will be published on 6 May 2009

The interim report for the second quarter of 2009 will be published on 20 August 2009

The interim report for the third quarter of 2009 will be published on 20 November 2009

The interim year-end report for 2009 will be published on 19 February 2010

The information in this report is that which Ortivus is obliged
to publish in accordance with the Securities Market Act
The information was submitted for publication
at 9am on 23 February 2009

This interim report has not been audited by the company's auditors

For further information:

Jon Risfelt, Chairman of the Board, +46 (0)73-434 33 32
Håkan Cranning, CFO, telephone +46(0)8-446 45 00, or mobile +46 (0)73-834 46 18, or
E-mail: firstname.lastname@ortivus.com
Please also visit www.ortivus.com

CONSOLIDATED STATEMENT OF INCOME

<i>Amounts in SEK thousand</i>	<i>Oct. - Dec. 2008</i>	<i>Oct. - Dec. 2007</i>	<i>Jan. - Dec. 2008</i>	<i>Jan. - Dec. 2007</i>
Net sales	23 568	27 402	83 113	101 937
Cost of goods sold	-7 683	-7 692	-22 541	-25 819
Gross Profit	15 885	19 710	60 572	76 118
Other operating revenues	2 468	1 629	5 919	6 473
Selling expenses	-8 883	-11 994	-28 741	-44 658
Administrative expenses	-10 271	-6 028	-29 742	-34 511
Research and development costs	-18 927	-29 524	-41 574	-51 533
Other operating expenses	-4 841	-712	-8 290	-2 636
Operating profit/loss	-24 569	-26 919	-41 856	-50 747
Financial net	272	-604	-1 977	-391
Profit/loss after financial items	-24 297	-27 523	-43 833	-51 138
Current tax	982	-2 400	585	-4 589
Deferred tax	396	-6 152	-491	-4 415
Net result after tax continued operations	-22 919	-36 075	-43 739	-60 142
Net result after tax discontinued operations	0	-1 088	-25 207	-1 147
Net result after tax	-22 919	-37 163	-68 946	-61 289
Attributable to Equity holders of the Parent Company	-22 919	-37 163	-68 946	-61 289
Earnings per share - basic and diluted, SEK (earnings after tax/average number of shares)	-1,11	-1,79	-3,33	-2,96
Earnings per share - basic and diluted, SEK (From continued operations)	-1,11	-1,74	-2,11	-2,90
Number of shares as at closing day (thousands)	20 708	20 708	20 708	20 708
Average number of shares (thousands)	20 708	20 708	20 708	20 708
Depreciation and impairment of non-current assets:	11 537	25 620	52 181	39 521
- of which related to intangible fixed assets	10 517	22 262	47 154	31 320
- of which related to discontinued operations	0	301	30 023	832

Result after tax from discontinued operations is related to previous subsidiary Medos AG.

CONSOLIDATED BALANCE SHEET

<i>Amounts in SEK thousand</i>	<i>Dec. 31, 2008</i>	<i>Dec. 31, 2007</i>
Non-current assets		
Goodwill	49 956	63 859
Other intangible fixed assets	24 267	59 357
Plant, property, and equipment	9 515	13 049
Deferred tax assets	12 495	13 190
Total non-current assets	96 233	149 455
Current assets		
Inventories	11 921	12 697
Current receivables	21 258	25 930
Short-term investments	1 355	8 188
Cash and cash equivalents	50 510	57 177
Total current assets	85 044	103 992
Total assets	181 277	253 447
Shareholders' equity	106 515	163 022
Non-current interest bearing liabilities	28 805	12 877
Other non-current liabilities	567	9 420
Current interest bearing liabilities	0	8 644
Other current liabilities	45 390	59 484
Total shareholders' equity and liabilities	181 277	253 447
Pledged security and potential obligations		
Pledged security	16 355	23 188
Potential obligations	6 646	7 626

CONSOLIDATED STATEMENT OF CASH FLOW

<i>Amounts in SEK thousand</i>	<i>Oct. - Dec. 2008</i>	<i>Oct. - Dec. 2007</i>	<i>Jan. - Dec. 2008</i>	<i>Jan. - Dec. 2007</i>
Cash flow from operating activities	-6 356	-1 433	-18 976	-1 396
Cash flow from investment activities	4 232	-2 204	-370	-22 999
Cash flow from financing activities	-1 101	-2 176	8 222	-8 547
Cash flow for the period	-3 225	-5 813	-11 124	-32 942

CHANGE IN CONSOLIDATED SHAREHOLDER'S EQUITY

<i>Amounts in SEK thousand</i>	<i>Jan. - Dec. 2008</i>	<i>Jan. - Dec. 2007</i>
Opening balance	163 022	226 029
Warrants	500	-
Translation differences	11 939	-1 718
Result for the period	-68 946	-61 289
Closing balance	106 515	163 022

GROUP KEY FINANCIAL MEASURES

	<i>2008</i>	<i>2007</i>	<i>2006</i>	<i>2005</i>
Net result after tax	-68 946	-61 289	-149 186	-17 713
Net result margin, %	-53	-50	-64	-10
Earnings per share - basic and diluted, SEK ¹⁾	-3,33	-2,96	-8,51	-1,22
Return on shareholders' equity, % ²⁾	neg	neg	neg	neg
Return on capital employed, % ²⁾	neg	neg	neg	neg
Equity/assets ratio, %	59	64	68	64
Debt/equity ratio, X	0,27	0,13	0,16	0,17
Equity per share, SEK	5,14	7,87	10,92	16,64
Average number of employees	98	157	172	144

¹⁾ Restated for bonus issue-effect on new share issue 2006 and earlier years.

²⁾ On rolling 12-month basis.

PARENT COMPANY INCOME STATEMENT

<i>Amounts in SEK thousand</i>	<i>Oct. - Dec. 2008</i>	<i>Oct. - Dec. 2007</i>	<i>Jan. - Dec. 2008</i>	<i>Jan. - Dec. 2007</i>
Net sales	6 909	9 222	24 414	26 450
Cost of goods sold	-3 662	-3 571	-11 870	-12 232
Gross Profit	3 247	5 651	12 544	14 218
Operating costs	-11 146	-25 330	-40 757	-72 177
Operating profit/loss	-7 898	-19 679	-28 213	-57 959
Net financial items	13 035	-1 069	-27 269	-1 232
Profit/loss after financial items	5 137	-20 748	-55 482	-59 191
Net result after tax	5 137	-20 748	-55 482	-59 191
Depreciation and impairment of non-current assets:	1 651	21 708	45 645	29 678
- of which related to intangible fixed assets	1 261	21 305	5 371	27 874

In result after financial items a write-down of shares in Medos AG on June 30th 2008, is included with KSEK 38 682 and dividends from subsidiarys KSEK 12 865.

PARENT COMPANY BALANCE SHEET

<i>Amounts in SEK thousand</i>	<i>Dec. 31, 2008</i>	<i>Dec. 31, 2007</i>
Non-current assets		
Intangible assets	24 268	25 113
Tangible assets	3 940	5 107
Shares in Group companies	96 637	132 442
Total non-current assets	124 845	162 662
Current assets		
Inventories	11 353	7 630
Current receivables	17 087	37 146
Cash and bank deposits	20 733	22 177
Total current assets	49 173	66 953
Total assets	174 018	229 615
Shareholders' equity	133 192	188 173
Provisions	567	3 270
Non-current liabilities	28 750	12 397
Current liabilities to credit institutions	0	8 265
Other current liabilities	11 509	17 510
Total shareholders' equity and liabilities	174 018	229 615
Pledged security and potential obligations		
Pledged security	15 000	15 000
Potential obligations	6 646	7 970

HEAD OFFICE

Ortivus AB

Box 713
Karlsrovägen 2D
182 17 Danderyd
Sverige
Telefon: +46 8 446 45 00
Telefax: +46 8 446 45 19
E-post: info@ortivus.com
www.ortivus.com

SUBSIDIARIES

Ortivus North America, Inc.

PO Box 276
2324 Sweet Parkway Rd.
Decorah, IA 52101-0276
USA
Telefon: +1 563 387 3191
Telefax: +1 563 387 9333
E-post: sales@ortivusna.com
www.ortivusna.com

Ortivus North America, Inc.

2525 Daniel Johnson Boulevard, Suite 300
Laval, Quebec
H7T 1S9
Canada
Telephone: +1 450 682 6262
Fax: +1 450 682 8117
E-mail: sales@ortivusna.com
www.ortivusna.com

Ortivus UK Ltd

2 Turnberry House
Solent Business Park
Fareham, Hants PO15 7FJ
Storbritannien
Telefon: +44 1489 889201
Telefax: +44 1489 889206
E-post: sales@ortivus.co.uk
www.ortivus.com